Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated: April 2, 2026, 3:08 am
Author: Getaka|Social: XLinkedIn

Jagsonpal Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis

Fair Value

₹166.90Overvalued by 10.27%vs CMP ₹186.00

P/E (29.2) × ROE (18.6%) × BV (₹37.90) × DY (1.35%)

₹92.78Overvalued by 50.12%vs CMP ₹186.00
MoS: -100.5% (Negative)Confidence: 66/100 (Moderate)Models: 1 Fair, 9 Over
ModelCategoryValueWeightSignal
PE-ROEEarnings₹194.1821%Fair (+4.4%)
Graham NumberEarnings₹72.3615%Over (-61.1%)
Earnings PowerEarnings₹37.1010%Over (-80.1%)
DCFCash Flow₹129.5810%Over (-30.3%)
Net Asset ValueAssets₹37.867%Over (-79.6%)
EV/EBITDAEnterprise₹69.288%Over (-62.8%)
Dividend DiscountDividends₹55.008%Over (-70.4%)
Earnings YieldEarnings₹61.407%Over (-67%)
ROCE CapitalReturns₹60.578%Over (-67.4%)
Revenue MultipleRevenue₹40.255%Over (-78.4%)
Consensus (10 models)₹92.78100%Overvalued
Key Drivers: Wide model spread (₹37–₹194) — high uncertainty.

PE-ROE · Graham · EPV · DCF · NAV · EV/EBITDA · DDM · Earnings Yield · ROCE Capital · Revenue Multiple | CoE: 12% · Terminal: 4% · EPS CAGR: 16.3%

*Investments are subject to market risks

Investment Snapshot

71
Jagsonpal Pharmaceuticals Ltd scores 71/100 (Strong)
Based on 5 dimensions: health, institutional flow, earnings quality, momentum, and peer comparison
Stock Health92/100 · Strong
ROCE 23.0% ExcellentROE 18.6% ExcellentD/E 0.05 Low debtInterest Coverage 0.0x RiskyProfitable 5/5 years Consistent
Smart Money60/100 · Moderate
FII holding up 0.02% (6mo) Slight increasePromoter holding at 67.4% Stable
Earnings Quality60/100 · Moderate
OPM stable around 15% SteadyWorking capital: 9 days (improving) Efficient
Quarterly Momentum50/100 · Moderate
Revenue (4Q): +11% YoY GrowingProfit (4Q): -19% YoY Declining
Industry Rank85/100 · Strong
P/E 29.2 vs industry 53.8 Cheaper than peersROCE 23.0% vs industry 16.4% Above peersROE 18.6% vs industry 15.2% Above peers3Y sales CAGR: 7% Slow

Weights: Health 30% · Earnings Quality 25% · Momentum 20% · Industry Rank 15% · Smart Money 10%. Scores are computed from reported financials and recalculated daily. Not investment advice.

Share Price and Basic Stock Data

Last Updated: April 2, 2026, 3:08 am

Market Cap 1,243 Cr.
Current Price 186
Intrinsic Value₹92.78
High / Low 302/155
Stock P/E29.2
Book Value 37.9
Dividend Yield1.35 %
ROCE23.0 %
ROE18.6 %
Face Value 2.00
PEG Ratio1.79

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Jagsonpal Pharmaceuticals Ltd

Competitors

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
Jagsonpal Pharmaceuticals Ltd 1,243 Cr. 186 302/15529.2 37.91.35 %23.0 %18.6 % 2.00
Beta Drugs Ltd 1,287 Cr. 1,270 2,000/99029.9 2190.00 %27.0 %25.9 % 10.0
Lincoln Pharmaceuticals Ltd 1,191 Cr. 595 679/44013.6 3570.30 %17.3 %12.8 % 10.0
Hester Biosciences Ltd 1,162 Cr. 1,366 2,350/1,23928.4 3970.51 %9.71 %9.18 % 10.0
Venus Remedies Ltd 1,151 Cr. 861 950/28615.1 4450.00 %11.1 %7.16 % 10.0
Industry Average19,815.15 Cr1,053.8453.84201.200.39%16.35%15.16%6.10

All Competitor Stocks of Jagsonpal Pharmaceuticals Ltd

Quarterly Result

MetricDec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales 60556058474361757459767473
Expenses 52505249444151585850615857
Operating Profit 9598331016169141616
OPM % 14%10%14%14%7%6%17%22%21%15%19%22%22%
Other Income 232232-22263331
Interest 0000000000000
Depreciation 0000001222222
Profit before tax 107101055715399141715
Tax % 21%24%26%25%25%22%25%25%17%24%25%25%25%
Net Profit 867744511327111311
EPS in Rs 1.190.851.141.140.600.540.811.734.820.991.621.891.64

Last Updated: February 5, 2026, 11:09 am

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: February 24, 2026, 3:16 pm

MetricMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Sales 144138143144127167159188218237209269282
Expenses 133129132138138157150169192203186218226
Operating Profit 119126-1199192634235156
OPM % 7%6%8%4%-9%6%5%10%12%14%11%19%20%
Other Income 001130134329289
Interest 5453111100111
Depreciation 3332011121289
Profit before tax 32414-1299222735307054
Tax % 16%30%20%18%-1%20%16%22%29%23%25%21%
Net Profit 21312-1278171927225541
EPS in Rs 0.320.180.501.81-1.761.101.202.602.884.083.408.346.14
Dividend Payout % 62%22%8%2%-2%9%17%15%56%49%59%30%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-20242024-2025
YoY Net Profit Growth (%)-50.00%200.00%300.00%-200.00%158.33%14.29%112.50%11.76%42.11%-18.52%150.00%
Change in YoY Net Profit Growth (%)0.00%250.00%100.00%-500.00%358.33%-144.05%98.21%-100.74%30.34%-60.62%168.52%

Jagsonpal Pharmaceuticals Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:7%
5 Years:11%
3 Years:7%
TTM:35%
Compounded Profit Growth
10 Years:42%
5 Years:38%
3 Years:29%
TTM:87%
Stock Price CAGR
10 Years:36%
5 Years:75%
3 Years:16%
1 Year:45%
Return on Equity
10 Years:10%
5 Years:16%
3 Years:17%
Last Year:19%

Last Updated: September 5, 2025, 8:00 am

Balance Sheet

Last Updated: December 10, 2025, 2:53 am

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Sep 2025
Equity Capital 13131313131313131313131313
Reserves 85828597859198109120146174227240
Borrowings 3639388845706999
Other Liabilities 22192225232831353130212937
Total Liabilities 156154159143130136147164164195217278299
Fixed Assets 5652522221222226232499490
CWIP 2000344000000
Investments 0000001115511000
Other Assets 9810210812110511010912391170208184209
Total Assets 156154159143130136147164164195217278299

Reserves and Borrowings Chart

Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Cash from Operating Activity + 849-3-23111287473555
Cash from Investing Activity + -1-0-241-3-1-11-2-26-58-25-45
Cash from Financing Activity + -4-1-6-34-1-6-1-7-18-0-9-12
Net Cash Flow 2215-624-019-36-112-2
Free Cash Flow 64640-53012286483591
CFO/OP 75%53%83%-6%14%311%150%164%54%158%189%124%

Free Cash Flow

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Free Cash Flow-25.00-30.00-26.00-2.00-19.005.004.0012.0026.0028.0014.0042.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Debtor Days 1151191061007345492526321918
Inventory Days 173176246295307164191134122826858
Days Payable 294260565459768276663537
Cash Conversion Cycle 2592522923393251501647772485339
Working Capital Days 6468721541496755325934529
ROCE %6%5%7%3%-10%9%9%18%20%25%17%23%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthMar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Promoters 68.72%68.72%68.72%68.48%68.09%68.04%67.98%67.82%67.77%67.65%67.54%67.39%
FIIs 0.10%0.37%0.38%0.53%0.73%1.10%2.30%2.10%2.10%2.17%2.12%2.12%
DIIs 0.82%0.82%0.82%0.82%0.84%0.84%0.11%0.00%0.00%0.05%0.08%0.15%
Public 30.34%30.07%30.07%30.16%30.33%30.01%29.63%30.10%30.11%30.12%30.25%30.34%
No. of Shareholders 14,08413,78216,04115,78516,28215,74815,63318,47121,08522,89924,65324,895

Shareholding Pattern Chart

No. of Shareholders

Jagsonpal Pharmaceuticals Ltd: Intrinsic Value & Share Price Analysis - Shareholder trend analysis

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Motilal Oswal S&P BSE Healthcare ETF 83 0.04 0832025-04-22 17:25:300%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 25Mar 24Mar 23Mar 22Mar 21
FaceValue 2.005.005.005.005.00
Basic EPS (Rs.) 8.268.4910.207.486.51
Diluted EPS (Rs.) 8.228.4610.207.486.51
Cash EPS (Rs.) 9.569.1310.668.066.71
Book Value[Excl.RevalReserv]/Share (Rs.) 36.0870.8860.6546.9643.55
Book Value[Incl.RevalReserv]/Share (Rs.) 36.0870.8860.6549.9546.54
Dividend / Share (Rs.) 2.505.005.004.001.00
Revenue From Operations / Share (Rs.) 40.4778.9490.3686.3071.74
PBDIT / Share (Rs.) 8.9212.2315.2211.128.96
PBIT / Share (Rs.) 7.7011.6114.7610.548.76
PBT / Share (Rs.) 10.5211.3013.2910.438.35
Net Profit / Share (Rs.) 8.348.5010.207.486.51
PBDIT Margin (%) 22.0515.4916.8412.8812.48
PBIT Margin (%) 19.0214.7016.3412.2012.21
PBT Margin (%) 25.9914.3114.7012.0811.63
Net Profit Margin (%) 20.6010.7611.288.669.07
Return on Networth / Equity (%) 23.1111.9816.8115.9214.95
Return on Capital Employeed (%) 20.2615.5023.1020.5518.54
Return On Assets (%) 19.8910.3413.7011.6210.38
Total Debt / Equity (X) 0.000.000.000.000.05
Asset Turnover Ratio (%) 1.081.011.301.361.21
Current Ratio (X) 6.2210.425.973.242.98
Quick Ratio (X) 5.649.635.222.372.25
Inventory Turnover Ratio (X) 17.801.241.241.361.31
Dividend Payout Ratio (NP) (%) 23.8958.310.0053.5015.35
Dividend Payout Ratio (CP) (%) 20.8354.290.0049.6314.91
Earning Retention Ratio (%) 76.1141.690.0046.5084.65
Cash Earning Retention Ratio (%) 79.1745.710.0050.3785.09
Interest Coverage Ratio (X) 61.8639.7496.57102.1821.61
Interest Coverage Ratio (Post Tax) (X) 38.2428.6074.0869.7016.71
Enterprise Value (Cr.) 1305.18591.93644.85795.42154.96
EV / Net Operating Revenue (X) 4.862.842.723.520.82
EV / EBITDA (X) 22.0218.3016.1727.316.60
MarketCap / Net Operating Revenue (X) 5.343.543.213.631.11
Retention Ratios (%) 76.1041.680.0046.4984.64
Price / BV (X) 5.993.954.786.681.83
Price / Net Operating Revenue (X) 5.343.543.213.631.11
EarningsYield 0.030.030.030.020.08

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

About the Company - Qualitative Analysis

Jagsonpal Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 17/08/1978 and has its registered office in the State of Delhi, India. Company's Corporate Identification Number(CIN) is L74899DL1978PLC009181 and registration number is 009181. Currently Company is involved in the business activities of Manufacture of allopathic pharmaceutical preparations. Company's Total Operating Revenue is Rs. 268.72 Cr. and Equity Capital is Rs. 13.28 Cr. for the Year ended 31/03/2025.
INDUSTRYADDRESSCONTACT
PharmaceuticalsInnov8 3rd Floor, New Delhi Delhi 110020Contact not found
Management
NamePosition Held
Mr. Rajpal Singh KochharChairman Emeritus
Mr. Harsha RaghavanChairman & Non-Exe.Director
Mr. Manish GuptaManaging Director
Mr. Prithipal Singh KochharNon Executive Director
Mr. Debasis Bikash NandyIndependent Director
Ms. Radhika Madhukar DudhatIndependent Director
Ms. Pallavi Dinodia GuptaIndependent Director

FAQ

What is the intrinsic value of Jagsonpal Pharmaceuticals Ltd and is it undervalued?

As of 09 April 2026, Jagsonpal Pharmaceuticals Ltd's intrinsic value is ₹92.78, which is 50.12% lower than the current market price of ₹186.00, suggesting the stock is overvalued. This is calculated using the PE ratio method factoring in ROE (18.6 %), book value (₹37.9), dividend yield (1.35 %), and 5-year EPS CAGR.

What is the current share price and 52-week range of Jagsonpal Pharmaceuticals Ltd?

Jagsonpal Pharmaceuticals Ltd is trading at ₹186.00 as of 09 April 2026, with a FY2026-2027 high of ₹302 and low of ₹155. The stock is currently near its 52-week low. Market cap stands at ₹1,243 Cr..

How does Jagsonpal Pharmaceuticals Ltd's P/E ratio compare to its industry?

Jagsonpal Pharmaceuticals Ltd has a P/E ratio of 29.2, which is below the industry average of 53.84. This is broadly in line with or below the industry average.

Is Jagsonpal Pharmaceuticals Ltd financially healthy?

Key indicators for Jagsonpal Pharmaceuticals Ltd: ROCE of 23.0 % indicates efficient capital utilization; ROE of 18.6 % shows strong shareholder returns. Dividend yield is 1.35 %.

Is Jagsonpal Pharmaceuticals Ltd profitable and how is the profit trend?

Jagsonpal Pharmaceuticals Ltd reported a net profit of ₹55 Cr in Mar 2025 on revenue of ₹269 Cr. Compared to ₹19 Cr in Mar 2022, the net profit shows an improving trend.

Does Jagsonpal Pharmaceuticals Ltd pay dividends?

Jagsonpal Pharmaceuticals Ltd has a dividend yield of 1.35 % at the current price of ₹186.00. The company pays dividends, though the yield is modest.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Jagsonpal Pharmaceuticals Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE
Explore Industry-wise Stock Analysis Reports